GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Enliven Therapeutics
Shares of Enliven, a biotech company focused on targeted cancer therapy, reflect the progress of its clinical programs. Their price is highly volatile and depends on research results, partnerships, and the potential of its drugs.
Share prices of companies in the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company focused on targeted cancer therapy. This is its core segment. We classify it as part of the Oncology Targeted Therapy sector, and the chart below reflects the dynamics of this cutting-edge field of biotechnology.
Broad Market Index - GURU.Markets
Enliven Therapeutics is an oncology company developing targeted drugs for the treatment of blood cancers. Its innovations earn it a spot in the GURU.Markets index. The chart below represents the market. See how clinical trial successes are impacting this biotech company's stock.
Change in the price of a company, segment, and market as a whole per day
ELVN - Daily change in the company's share price Enliven Therapeutics
Daily fluctuations in Enliven Therapeutics, an oncology company, reflect the high risks and expectations of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for analysis of the targeted cancer therapy sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Enliven Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ELVN's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Enliven is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Enliven stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Enliven Therapeutics
Enliven is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Enliven Therapeutics, Inc. is a clinical-stage biotechnology company developing precision-targeted therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Enliven Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Enliven Therapeutics
The performance of Enliven, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its targeted oncology drugs, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing small-molecule drugs for targeted cancer therapy. Its goal is to create highly precise medications for patients with specific genetic mutations. The oncology sector chart will reflect overall investor interest in this field, providing a backdrop for assessing Enliven's scientific potential and risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies developing targeted cancer therapies are driven by news of clinical trials. The chart below shows the overall sentiment. Is Enliven Therapeutics following this trend, or are its R&D activities creating a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Enliven Therapeutics
Enliven Therapeutics, a clinical-stage biotech focused on targeted cancer therapy, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and drug efficacy data, reflecting the risks and hopes of precision oncology.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Enliven Therapeutics, like other biotech companies specializing in oncology, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general sentiment and how much by specific news about its drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Enliven Therapeutics is a biotech company developing cancer therapies. Its shares exist in a world of their own, where research data is king. The chart shows that ELVN's performance is largely uncorrelated with the market, driven by its unique development news.
Market capitalization of the company, segment and market as a whole
ELVN - Market capitalization of the company Enliven Therapeutics
The Enliven Therapeutics chart is a financial map of the precision fight against cancer. This biotech company's market cap reflects the hopes for its drugs, which target specific mutations that drive tumor growth. Its dynamics are a barometer of progress in clinical trials and the belief that precision oncology is the future of cancer treatment.
ELVN - Share of the company's market capitalization Enliven Therapeutics within the market segment - Oncology targeted therapy
Enliven Therapeutics is a biopharmaceutical company focused on developing precision cancer treatments. Its market capitalization reflects the potential of its targeted therapies for patients with specific genetic mutations. The chart below shows how the market views its scientific approach to oncology.
Market capitalization of the market segment - Oncology targeted therapy
Enliven Therapeutics is an oncology company developing targeted therapies. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investor hopes that targeted cancer therapy will become the future of treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Enliven Therapeutics is a biotech company focused on developing targeted therapies for cancer treatment. Its market cap is a financial bet on precision in oncology. Its value reflects investors' belief that their approach to creating "smart" drugs will lead to success in clinical trials.
Book value capitalization of the company, segment and market as a whole
ELVN - Book value capitalization of the company Enliven Therapeutics
Enliven Therapeutics is a biotech company, and its book value represents capital for clinical research. The chart below shows its financial resources for cancer drug development. This level is an indicator of the company's ability to finance long and expensive R&D projects.
ELVN - Share of the company's book capitalization Enliven Therapeutics within the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing cancer treatments. Its primary asset is research and development. The company's tangible asset share chart will be low, reflecting its focus on R&D, with laboratories serving as its primary assets rather than large manufacturing facilities.
Market segment balance sheet capitalization - Oncology targeted therapy
Enliven Therapeutics develops targeted drugs for cancer treatment. Its business is 100% focused on research and development. A book value chart shows that the company has virtually no tangible assets, as its primary assets are its intellectual property and scientific potential.
Book value of all companies included in the broad market index - GURU.Markets
Enliven Therapeutics' balance sheet is capital focused on targeted cancer treatment. The company's assets consist of rights to develop highly selective inhibitors and financial resources for clinical trials. The chart shows the size of its resources dedicated to developing drugs that hit the target precisely while minimizing side effects.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Enliven Therapeutics
Enliven Therapeutics is a biotechnology company developing targeted therapies for cancer. Its book value is cash. Its market capitalization is the net bet investors make on the success of its drug candidates in clinical trials and their potential to transform approaches to treating certain types of cancer.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing targeted therapies for cancer. Its value is entirely dependent on the success of its clinical programs. The chart shows how market expectations for its drug candidates compare to its book value, which is primarily comprised of cash.
Market to book capitalization ratio for the market as a whole
Enliven Therapeutics is a biotech company developing targeted cancer therapies. Its value depends almost entirely on the success of clinical trials. The chart demonstrates how the market valuation reflects investors' faith in science and future cash flows, rather than current tangible assets, which is typical for biotech.
Debts of the company, segment and market as a whole
ELVN - Company debts Enliven Therapeutics
Enliven Therapeutics, a biotech focused on targeted oncology, uses debt financing to advance its clinical research. This chart shows the company's capital raising to develop drugs for cancer patients who have developed resistance to existing treatments. Debt is a bet on scientific breakthroughs.
Market segment debts - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing targeted drugs for cancer treatment. At the clinical stage, funding expensive research is a key challenge, and debt can be part of a hybrid strategy. The chart shows how the company manages its finances during the long journey to potentially bringing the drug to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Enliven Therapeutics
Enliven Therapeutics is a biotech company developing targeted therapies for cancer. Financial stability is paramount during clinical trials. This chart shows whether the company uses debt. For investors, the absence of debt is a positive sign, mitigating risks on the long road to success.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing targeted drugs for cancer treatment. Its approach is aimed at overcoming resistance to existing therapies. This chart shows the overall debt burden in the sector, providing context for assessing how the company finances its expensive and highly specialized clinical trials.
Debt to book value of all companies in the market
Enliven Therapeutics, an oncology biotech, requires massive capital investment. This chart shows the overall market leverage, reflecting the availability of capital. It helps understand how easy or difficult it is for such companies to raise funding for their risky projects, depending on overall financial market sentiment.
P/E of the company, segment and market as a whole
P/E - Enliven Therapeutics
Enliven Therapeutics is a biotech company developing targeted cancer therapies. This chart reflects investors' faith in the rigor of its scientific approach. Its value reflects how the market perceives the potential of its drug candidates to treat specific cancer-causing mutations, promising future success.
P/E of the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company in the oncology sector. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to judge how highly the market values its targeted therapy drugs compared to the average prospects of other biotech companies operating in the same field.
P/E of the market as a whole
Enliven Therapeutics is a biotech company developing targeted drugs for cancer treatment. It focuses on precision medicine, creating treatments for patients with specific genetic mutations. The company's valuation is a bet on the success of its developments. This chart shows the overall interest in oncology, allowing one to understand whether Enliven's scientific approach stands out from the crowd of other oncology startups.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Enliven Therapeutics
Enliven Therapeutics is a biotechnology company focused on developing targeted cancer therapies. This chart reflects investor expectations for the clinical trials of its precision oncology drugs. The assessment is based on the potential of its molecules to effectively fight cancer cells while minimizing side effects.
%20P%2FE%20Enliven%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Enliven-Therapeutics&v=1772702431032 "Chart of the company's future (projected) P/E Enliven Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotech company developing precision cancer treatments. This chart compares the company's future profitability expectations with those of the oncology sector. It demonstrates the level of investor confidence in its scientific approach to targeted drug development and the potential of its leading clinical programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772702431037 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Enliven Therapeutics is a biotech company specializing in the development of targeted therapies for cancer treatment. Funding such cutting-edge research requires significant investment. This chart, showing overall market sentiment, reflects investor appetite for risk, which is critical for raising capital for drug development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702431040 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company specializing in the development of precision oncology therapies for cancer treatment. Its financial health is determined by research and development expenditures. This chart illustrates the company's financial trajectory, where investments in research and clinical trials are key to creating future value.
Profit of companies in the market segment - Oncology targeted therapy
Enliven Therapeutics is a biotechnology company specializing in the development of small-molecule drugs for targeted cancer therapy. This graph, showing overall sector profitability, reflects progress in cancer treatment. The success of Enliven's clinical programs could lead to new, effective treatments and impact the entire industry.
Overall market profit
Enliven Therapeutics develops precision cancer treatments that target specific mutations. This approach allows for the creation of more effective and less toxic drugs. The company is at the forefront of oncology, and its success depends on scientific discoveries and clinical trial results, not the general economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Enliven Therapeutics
Enliven Therapeutics is a biotechnology company specializing in the development of precision oncology drugs for patients with genetically determined cancers. The future profit projections you see are speculative and depend on the success of clinical trials. Analysts' expectations are based on the potential of its targeted therapies.
%20profit%20of%20the%20company%20Enliven%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Enliven-Therapeutics&v=1772702431104 "Graph of future (projected) profit of the company Enliven Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Enliven Therapeutics is a biopharmaceutical company developing small-molecule drugs for targeted cancer therapy. This chart shows future revenue expectations for the entire targeted cancer therapy segment. It allows one to assess how Enliven's scientific approach aligns with the overall financial outlook for this cutting-edge pharmaceutical field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772702431107 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Enliven Therapeutics is a biotech company developing targeted drugs for cancer treatment. Its value is determined by progress in clinical trials. This chart, which shows overall market sentiment, is important for Enliven because it impacts its access to funding. During periods of growth, investors are more likely to invest in promising but risky biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702431109 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotech company specializing in the development of targeted cancer treatments. For a company without commercial products, this chart is especially important. It reflects not current financial performance, but rather investors' faith in the company's scientific approach and the potential of its drugs to address unmet medical needs.
P/S market segment - Oncology targeted therapy
Enliven Therapeutics is a clinical-stage biotech company focused on developing precision oncology therapies for patients with cancer resistant to existing treatments. This chart shows how investors value revenue in the targeted therapy sector, demonstrating the level of optimism about Enliven's ability to develop effective treatments for complex cancer cases.
P/S of the market as a whole
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology drugs for the treatment of patients with cancer resistant to existing therapies. This chart, which displays the average valuation, demonstrates that the valuation of such companies is based on the future potential of their developments, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Enliven Therapeutics
Enliven Therapeutics is a biotechnology company developing targeted drugs for the treatment of oncology diseases. For a company in clinical development, this chart shows the market's assessment of its potential future revenue. It reflects investor confidence in the success of its precision oncology therapies and their commercial potential.
%20P%2FS%20Enliven%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Enliven-Therapeutics&v=1772702431139 "The graph of the company's future (projected) P/S Enliven Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Enliven Therapeutics is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for the treatment of cancer. Its estimated future revenue is reflected here. This high valuation reflects confidence in its approach to developing targeted therapies for patients with specific genetic mutations, a cutting-edge approach in oncology.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772702431144 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Enliven Therapeutics is a biotech company developing targeted cancer drugs that target specific mutations. Its future depends on the success of clinical trials. This chart of overall market expectations reflects investor belief that personalized medicine and precision oncology are the future of cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702431146 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Enliven Therapeutics
Enliven Therapeutics is at the forefront of targeted cancer therapy development. As a clinical-stage company, its revenue is generated not from sales but from partnerships. This graph reflects the receipt of upfront and milestone payments, which validate the scientific value of its developments for major pharmaceutical players.
Sales of companies in the market segment - Oncology targeted therapy
Enliven Therapeutics is a precision oncology biotechnology company developing small-molecule drugs targeting key oncogenic drivers for cancer treatment. This chart represents the total revenue of the entire targeted therapy market, illustrating the commercial potential for innovative and targeted approaches to cancer treatment.
Overall market sales
Enliven Therapeutics, Inc. is a biotechnology company specializing in the development of precision oncology drugs. Its value is determined by clinical trial success. Its business is not dependent on consumer cycles, but the overall economic environment, shown in this chart, influences the availability of capital for R&D and the strategic partnership decisions of large pharmaceutical companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company specializing in the development of targeted cancer treatments. Future revenue is dependent on the success of its clinical programs and drug approvals. This chart represents analysts' long-term forecast based on the potential of its innovative approaches in oncology.
%20sales%20of%20the%20company%20Enliven%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Enliven-Therapeutics&v=1772702431164 "Schedule of future (projected) sales of the company Enliven Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Enliven Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapies for cancer treatment. This forecast chart reflects the potential future revenue of their leading drug candidates. This is an analyst's view of the commercial prospects of their targeted therapies in the competitive oncology development landscape.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772702431182 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Enliven Therapeutics. The company develops drugs for targeted cancer therapy. Funding for its research depends on capital inflows into the sector, which correlates with the overall state of financial markets and investor risk appetite.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702431186 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Enliven Therapeutics
Enliven Therapeutics is a biotechnology company focused on developing targeted therapies for cancer treatment. This chart reflects its current status as a research and development organization. Future profitability depends entirely on the success of clinical trials and the commercialization of its targeted inhibitors, which target specific mutations in cancer cells.
Market segment marginality - Oncology targeted therapy
Enliven Therapeutics is a biotech company focused on developing small-molecule kinase inhibitors for the treatment of cancer. Profitability depends on the success of its targeted therapies in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential of Enliven's targeted approach to cancer treatment.
Market marginality as a whole
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its valuation is dependent on success in research and development. This chart reflects the general investor willingness to finance long-term and risky biotech projects, which is critical to Enliven's survival and growth.
Employees in the company, segment and market as a whole
Number of employees in the company Enliven Therapeutics
Enliven Therapeutics is a biotechnology company developing small-molecule kinase inhibitors for the treatment of cancer. This chart reflects the size of the scientific team focused on advancing its drug candidates through clinical trials. Growth is expected as programs progress and the need to expand clinical and regulatory functions arises.
Share of the company's employees Enliven Therapeutics within the market segment - Oncology targeted therapy
Enliven Therapeutics develops highly targeted cancer therapies that target specific mutations. Its team of scientists is working to create treatments for patients with limited treatment options. This chart shows the company's share of the total number of researchers in the field of targeted oncology, reflecting its scientific potential and focus on personalized medicine.
Number of employees in the market segment - Oncology targeted therapy
Enliven Therapeutics is a biopharmaceutical company focused on developing precision oncology drugs for the treatment of patients with genetically determined cancers. This chart shows employment in the targeted oncology sector. The growing number of scientists in this field reflects advances in understanding cancer genetics and the desire to create more personalized treatments.
Number of employees in the market as a whole
Enliven Therapeutics is a biotech company specializing in precision oncology. Their goal is to create targeted drugs for cancer treatment. This overall workforce schedule is irrelevant to them. Their growth and staffing needs are determined solely by progress in their research and clinical programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Enliven Therapeutics (ELVN)
Enliven Therapeutics is a clinical-stage biotech company specializing in precision oncology. Its valuation is based on the potential of its drug candidates. This chart for such companies typically shows a very high cost per employee, as investors value the science generated by a small, focused team.
%20of%20the%20company%20Enliven%20Therapeutics%20(ELVN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Enliven-Therapeutics-ELVN&v=1772702431264 "Chart of market capitalization per employee (in thousands of dollars) of the company Enliven Therapeutics (ELVN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Enliven Therapeutics (ELVN) is a biotech company specializing in the development of kinase inhibitors (targeted therapy) for cancer treatment. Their value lies in their R&D pipeline. This chart reflects the high market valuation of their scientific potential per team.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772702431272 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Enliven Therapeutics is a biotech company specializing in the development of targeted therapies for cancer treatment. The market capitalization of such companies is determined by the potential of their scientific research. This chart shows a very high valuation per employee, as investors believe that a small team of scientists can create a drug that will transform approaches to cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702431280 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Enliven Therapeutics (ELVN)
Enliven Therapeutics is a biotech company developing targeted cancer therapies. They target specific mutations. This is pure R&D. This chart doesn't show profit, but rather the company's "burn rate": how much the company spends (negative profit) on each scientist during the development of these precision-engineered drugs.
%20Chart%20Enliven%20Therapeutics%20(ELVN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Enliven-Therapeutics-ELVN&v=1772702431284 "Company Profit Per Employee (in thousands of dollars) Chart Enliven Therapeutics (ELVN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Enliven Therapeutics is a clinical-stage biotech company developing targeted therapies (inhibitors) for the treatment of cancer. This chart shows the benchmark for the "Biotech" sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772702431293 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Enliven Therapeutics is a biotech company focused on "precision oncology." They develop drugs that target specific mutations that cause cancer. This R&D business is at the forefront of science. This graph helps us understand how a model where value is created by the intellectual labor of a small group of scientists compares to staff efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702431301 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Enliven Therapeutics (ELVN)
Enliven Therapeutics is a biotech company specializing in precision oncology. While in clinical development, it does not yet have any commercial products. This graph would show zero or minimal revenue, which is typical for R&D companies whose value lies in the potential of their scientific discoveries and future drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Enliven-Therapeutics-ELVN&v=1772702431303 "Sales chart per company employee Enliven Therapeutics (ELVN)")
Sales per employee in the market segment - Oncology targeted therapy
Enliven Therapeutics is a clinical-stage biotech company developing targeted cancer therapies. They target specific mutations that cause the disease. This graph reflects their R&D status. The productivity of their scientific team is measured not by current sales, but by progress in clinical trials, which creates future value.
Sales per employee for the market as a whole
Enliven Therapeutics (ELVN) is a clinical-stage biotech company specializing in the development of precision oncology—drugs that target specific mutations that cause cancer. This is cutting-edge science. Like other clinical-stage biotechs, Enliven has no commercial revenue. This schedule will be zero or reflect milestone payments from partners. The entire staff (scientists) is currently a cost center.
Short shares by company, segment and market as a whole
Shares shorted by company Enliven Therapeutics (ELVN)
Enliven Therapeutics is a clinical-stage biotech developing targeted drugs (kinase inhibitors) for the treatment of specific types of cancer. This chart shows the level of skepticism. Bears are betting on the high risk of failure in clinical trials or that even if successful, their drugs will target too narrow (niche) patient groups, limiting their commercial potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Enliven-Therapeutics-ELVN&v=1772702431326 "Short Shares Chart for the Company Enliven Therapeutics (ELVN)")
Shares shorted by market segment - Oncology targeted therapy
Enliven Therapeutics (ELVN) is a biotech company developing targeted drugs for the treatment of cancer, particularly chronic myeloid leukemia. This chart shows bets against the targeted oncology sector. Shorts in this sector reflect investors' doubts about the ability of smaller companies to compete with pharmaceutical giants in developing new oncology drugs.
Shares shorted by the overall market
Enliven Therapeutics is a clinical-stage biotech developing cancer drugs. Its shares are a bet on future success. When this overall pessimism indicator rises, investors are unwilling to wait. They are dumping unprofitable companies en masse that require constant refinancing to continue research, like ELVN.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Enliven Therapeutics (ELVN)
Enliven Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech, indicating potential pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Enliven-Therapeutics-ELVN&v=1772702431355 "RSI 14 indicator chart for the company's stock Enliven Therapeutics (ELVN)")
RSI 14 Market Segment - Oncology targeted therapy
Enliven Therapeutics is a biopharmaceutical company developing small-molecule drugs (targeted therapies) for the treatment of cancer. Its approach is aimed at overcoming resistance to existing treatments. This chart shows the overall sentiment in the targeted oncotherapy sector. It helps separate the ELVN dynamics from the general "noise" in the biotech sector.
RSI 14 for the overall market
Enliven Therapeutics (ELVN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ELVN (Enliven Therapeutics)
Enliven Therapeutics (ELVN) is a clinical-stage biopharmaceutical company specializing in precision oncology. It develops kinase inhibitors (small molecules) for the treatment of cancer. This chart shows the average 12-month analyst forecast, reflecting their assessment of the preclinical and early clinical data for the company's drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ELVN-Enliven-Therapeutics&v=1772702431367 "A chart showing analyst consensus forecasts for the expected stock price. ELVN (Enliven Therapeutics)")
The difference between the consensus estimate and the actual stock price ELVN (Enliven Therapeutics)
Enliven (ELVN) is a clinical-stage biotech focused on precision oncology. It develops targeted drugs to combat cancer at the molecular level. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the company's science and R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ELVN-Enliven-Therapeutics&v=1772702431377 "A chart showing the difference between the consensus forecast and the actual stock price. ELVN (Enliven Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Enliven Therapeutics is a clinical-stage biotech company developing small molecules (tablets) for targeted cancer therapy, aiming to improve existing drugs. This chart shows general expectations for the targeted oncology sector. It reflects whether experts believe in the "best-in-class" drug strategy.
Analysts' consensus forecast for the overall market share price
Enliven Therapeutics (ELVN) is a cutting-edge biotech developing targeted therapies for cancer. It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotech focused on developing targeted therapies for rare cancers. They target specific mutations that are difficult to treat. This graph is a pure reflection of their science. Its performance is entirely dependent on the results of their clinical trials and the market's confidence in their R&D pipeline.
AKIMA Market Segment Index - Oncology targeted therapy
Enliven (ELVN) is a clinical-stage biotech focused on precision oncology (cancer); the company is developing next-generation targeted therapies (BCR-ABL inhibitors) for the treatment of blood cancer (CML). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (CML) R&D focus (ELVN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Enliven Therapeutics is a biotech company developing small molecules for cancer treatment (targeted therapy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early-clinical stage research company compares to the overall economic trends affecting the biotech sector.
